Non-invasive splenic parameters of portal hypertension: Assessment and utility

doi:10.4254/wjh.v12.i11.1055

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6375)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

332

WORD

216

HTML

3319

Figures (1-3)

334

Tables (1-4)

246

Sum=4447

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

545

Download

1383

Sum=1928

Nov 27, 2020 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Nov 27, 2020; 12(11): 1055-1066
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1055

Table 1 Baseline characteristics of the patient population

Parameter	Mean (standard deviation) or n
Parameter	Groups 1 and 2 (n = 50)	Group 1 (n = 25)	Group 2 (n = 25)
Age	57.86 (12.22)	60.44 (9.89)	55.28 (13.90)
Sex (M:F)	31:19	15:10	16:9
BMI	29.42 (7.61)	28.59 (5.76)	30.31 (9.26)
Skin to liver capsule Distance (cm)	2.43 (0.99)	2.46 (1.01)	2.40 (0.99)
METAVIR score	3.13 (1.276)	3.74 (0.752)	2.52 (1.410)
ALD	12	7	5
NAFLD	12	4	8
ALD and NAFLD	4	3	1
HCV	2	2	0
AIH	3	0	3
Miscellaneous	17	9	9
Total bilirubin (μmol/L)	28.00 (44.728)	39.92 (60.139)	16.08 (13.108)
ALP (IU/L)	127.33 (66.902)	144.56 (75.900)	109.38 (51.679)
GGT (IU/L)	147.68 (192.683)	160.96 (166.671)	134.96 (217.570)
ALT (IU/L)	60.84 (12.219)	48.52 (29.427)	73.16 (83.490)
AST (IU/L)	62.50 (49.043)	64.88 (32.720)	60.12 (61.872)
Albumin (g/L)	34.10 (6.129)	30.88 (5.761)	37.32 (4.679)
Platelet count (× 10⁹)	151.42 (73.016)	112.16 (60.023)	190.68 (63.804)
Prothrombin time (sec)	12.572 (1.9886)	13.470 (2.2077)	11.540 (1.0007)
INR	1.184 (0.1742)	1.260 (0.1871)	1.108 (0.1222)
EGD (PH present)	25	25	0
HVPG (PH present)	5	5	0

Group 1: Population with evidence of portal hypertension; Group 2: Population with no evidence of portal hypertension. BMI: Body mass index; ALD: Aldosterone; NAFLD: Non-alcoholic fatty liver disease; HCV: Hepatitis C virus; AIH: Autoimmune hepatitis; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio; EGD: Esophago-gastroduodenoscopy; HVPG: Hepatic venous pressure gradient; PH: Portal hypertension.

Table 2 Univariate analysis showing association of clinical parameters with clinically significant portal hypertension

Variable	Odds ratio	Cut-off	P value	Estimated AUROC curve	P value of AUROC
BMI	0.969	> 26.42	0.425	0.506	0.951
ALT (IU/L)	0.993	> 94.00	0.147	0.514	0.869
AST (IU/L)	1.002	> 64.00	0.728	0.652	0.065
GGT (IU/L)	1.001	> 85.00	0.639	0.643	0.094
ALP (IU/L)	1.001	> 96.00	0.050	0.678	0.033
Bilirubin	1.037	> 11.00	0.013^a	0.722	0.007^b
Platelet count (× 10⁹)	0.979	< 126.00	< 0.001^c	0.846	< 0.001
Albumin (g/L)	0.786	< 33.00	< 0.001^c	0.820	< 0.001^c
Prothrombin time (sec)	2.721	> 12.20	< 0.001^c	0.800	< 0.001^c
APRI score	2.030	> 0.81	0.008^b	0.827	< 0.001^c
ElastPQ median liver stiffness (kPa)	1.048	> 10.16	0.021^a	0.657	0.061
ElastPQ median spleen stiffness (kPa)	1.007	> 29.99	0.368	0.712	0.010^b
ElastPQ spleen area (cm²)	1.075	> 57.90	< 0.001^c	0.828	0.002^c
ElastPQ spleen diameter (cm)	1.651	> 13.90	0.002^c	0.804	0.007^b

^aP < 0.05.

^bP < 0.01.

^cP < 0.005. AUROC: Area under the receiver operating characteristic; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: γ-glutamyl transpeptidase; ALP: Alkaline phosphatase; APRI: AST-to-platelet-ratio-index; ElastPQ: Elastography point quantification.

Table 3 Diagnostic performance of combination variables as predictors of clinically significant portal hypertension

Variables	AUROC curve	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
ElastPQ median spleen area (> 57.90 cm²) and Platelet count (< 126 × 10⁹)	0.875	63.2	100.0	100.0	61.1
ElastPQ median spleen stiffness (> 29.99 kPa) and platelet count (< 126 × 10⁹)	0.855	88.0	75.00	78.6	85.7

AUROC: Area under the receiver operating characteristic; ElastPQ: Elastography point quantification.

Table 4 One-way random intraclass coefficient values for inter-operator variability

	Spleen area	Spleen diameter
Number of operators	2	2
Number of measurements	19	19
Mean	0.98	0.96
95% confidence interval	0.94-0.99	0.91-0.99

Citation: Ahmad AK, Atzori S, Maurice J, Taylor-Robinson SD, Lim AKP. Non-invasive splenic parameters of portal hypertension: Assessment and utility. World J Hepatol 2020; 12(11): 1055-1066
URL: https://www.wjgnet.com/1948-5182/full/v12/i11/1055.htm
DOI: https://dx.doi.org/10.4254/wjh.v12.i11.1055